Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic dysfunction-associated steatohepatitis (MASH)

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty liver disease.

There could be a new use for semaglutide, the main ingredient of weight loss and diabetes drugs Wegovy and Ozempic. Dr. Jon LaPook explains a study sponsored by the drugmaker found it could treat a common liver disease by reducing inflammation and scarring.